Tyra Biosciences Inc
For the period ended Dec 31, 2023. Filed Mar 19, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 19, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Indicates management contract or compensatory plan.
- This certification is deemed not filed for purpose of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
TYRA BIOSCIENCES, INC.
/s/ Todd Harris, Ph.D.
Todd Harris, Ph.D.President, Chief Executive Officer, and Director
Date: March 19, 2024
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Todd Harris, Ph.D. | President, Chief Executive Officer and Director | March 19, 2024 |
| Todd Harris, Ph.D. | (principal executive officer) | |
| /s/ Alan Fuhrman | Chief Financial Officer | March 19, 2024 |
| Alan Fuhrman | (principal financial and accounting officer) | |
| /s/ Isan Chen, M.D. | Director | March 19, 2024 |
| Isan Chen, M.D. | ||
| /s/ Gilla Kaplan, Ph.D. | Director | March 19, 2024 |
| Gilla Kaplan, Ph.D. | ||
| /s/ Nina Kjellson | Director | March 19, 2024 |
| Nina Kjellson | ||
| /s/ Melissa McCracken, Ph.D. | Director | March 19, 2024 |
| Melissa McCracken, Ph.D. | ||
| /s/ Robert More | Director | March 19, 2024 |
| Robert More | ||
| /s/ Jake Simson, Ph.D. | Director | March 19, 2024 |
| Jake Simson, Ph.D. | ||
| /s/ Siddarth Subramony, Ph.D. | Director | March 19, 2024 |
| Siddarth Subramony, Ph.D. | ||
| /s/ Rehan Verjee | Director | March 19, 2024 |
| Rehan Verjee | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.